Cancer News and Research

Latest Cancer News and Research

Researchers discover molecular signature to predict TB infection

Dallas scientists recently discovered a molecular signature in the blood of patients with tuberculosis (TB) that may explain why some people develop an active TB infection, while others exposed to the bacteria which causes the dangerous respiratory virus do not.

24 Sep 2010

New website offers real-life case studies and immunology breakthroughs on HIV

Amid a devastating HIV epidemic, some South African pediatricians treat as many as 100 children per day. With such overwhelming case loads, the physicians have little time to review the information they were offered in medical school on the topic of immunology. Recognizing the potential value of an understanding of up-to-date immunology in the treatment of HIV, immunologist Clive Gray developed Immunopaedia, a Web site that quickly and efficiently gives doctors a working knowledge of immunology through real-life case studies and news of immunology breakthroughs.

24 Sep 2010

Cianna Medical launches SAVI Sisters program to educate about breast cancer treatment options

Cianna Medical, Inc., the maker of the SAVI breast brachytherapy applicator, today announced the launch of SAVI Sisters, a program designed to provide education about breast cancer treatment options, primarily through social networking.

24 Sep 2010

CIC proposes criteria to improve endpoints for cancer immunotherapy trials

The Cancer Research Institute (CRI) Cancer Immunotherapy Consortium (CIC), the leading global initiative in advancing the emerging field of immuno-oncology, has proposed criteria for improved endpoints for cancer immunotherapy trials, which were published online on September 8 in the Journal of the National Cancer Institute.

24 Sep 2010

CAP meeting to highlight medical diagnostic procedures

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP).

24 Sep 2010

Breast cancer incidence drops, linked to decline in HRT use

A new Canadian study shows that a significant drop in breast cancer incidence among post-menopausal women from 2002 to 2004 coincided with a sharp drop in hormone replacement therapy (HRT) use during the same period. This is the first study to show the link between HRT use and breast cancer among Canadian women.

24 Sep 2010

Health Reform's Big Day: New consumer protections start now

Today marks the six month anniversary of enactment of the health reform law, and with it, a slew of consumer friendly provisions go into effect.

24 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

$Study finds high rate of C-sections in women suffering from pelvic fractures$

Study finds high rate of C-sections in women suffering from pelvic fractures

In research led by a Saint Louis University surgeon, investigators found that women who give birth after suffering pelvic fractures receive C-sections at more than double normal rates despite the fact that vaginal delivery after such injuries is possible. In addition, women reported lingering, yet often treatable, symptoms following their pelvic fracture injuries, from urinary complications to post-traumatic stress disorder.

24 Sep 2010

FDA approves Bionovo's CMC plan for Menerba drug candidate

Bionovo, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba, in a Type "B" or "End of Phase 2" meeting.

24 Sep 2010

Asbestos found in Queensland schools

Asbestos, known to be the cause of malignant mesothelioma, a rare and aggressive cancer for which there currently is no cure, is still found in the playground of Tewantin State School in Tewantin, Queensland, Australia. Since the beginning of 2009 asbestos has been reported numerous times at the school. Repeated exposures to the toxic material over 20 to 50 years may lead to this cancer.

24 Sep 2010

Researchers report MALAT1 gene regulates pre-mRNA splicing in cancer

Researchers report this month that MALAT1, a long non-coding RNA that is implicated in certain cancers, regulates pre-mRNA splicing a critical step in the earliest stage of protein production. Their study appears in the journal Molecular Cell.

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010.

24 Sep 2010

CytomX Therapeutics completes $30 million Series B financing

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.

23 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.

23 Sep 2010

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.

23 Sep 2010

MDS Nordion, Isotope enter framework agreement

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has entered into a framework agreement with The Open Joint Stock Company "Isotope" the authorized subsidiary of Rosatom State Corporation, to explore and define areas of collaboration in the field of supply, marketing and sale of isotopes produced in Russia.

23 Sep 2010

Golden Helix refactors HSPH's software for studying disease heritability in families

Today, Golden Helix, Inc., a global leader in genetic analysis solutions, announced a collaboration with Harvard School of Public Health (HSPH) under which Golden Helix is refactoring PBAT, HSPH's software for studying disease heritability in families.

23 Sep 2010